Neurocrine Biosciences chief commercial officer sells $251,426 in stock
Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently disclosed significant stock transactions. According to a Form 4 filing with the Securities and ...
Neurocrine Biosciences chief scientific officer sells $336,238 in stock
Onyia Jude, Chief Scientific Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), recently executed stock transactions involving the company's common shares. According to a recent SEC filing, Jude ...
Neurocrine Biosciences Reports Mixed Q4
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...
Neurocrine initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...
Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93
Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...